160 Bilder zum Thema "t cell receptor" bei ClipDealer

Medien sortieren nach     Gehe zu Seite:    
« Vorherige  1  2  3  
T-lymphocytes and dendritic cells, 3D-rendering; Dendritic cells are antigen-presenting cells of the immune system. They process antigen material and present it on the cell surface to the T-cells. Illustration
Engineered receptors (light blue) on the surface of a T-lymphocyte bind specifically to CD19-antigen molecules (magenta) on a leukemia cell. This activates a signal cascade in the T-cell leading to the segregation of vesicles that contain perforin an
Human Cytotoxic T cell
T Cells attacking Cancer Cells, 3D illustration
Human Cytotoxic T cell
T Cells attacking Cancer Cells 3D illustration
T Cells attacking Cancer Cells, 3D illustration
T Cells attacking Cancer Cells 3D illustration
Lymphocyte Cell Concept
T Cells attacking Cancer Cells 3D illustration
3d computer illustration of a chimeric antigen receptor. CARs are engineered cell receptors that allow T cells to recognize and attack cancer cells in a specific way. They are built by connecting several functional parts from different proteins.
Interactions of MHC-II with the T-cell receptor and CD4 and B7-1 with CD-28 activates T-cells while the interactions of P7-1 with CTLA-4 and PD-L1 with PD-1 deactivates T-cells.
Lymphocyte cell concept as an immune system cell representing the control of cancer through immunology or immunotherapy as an oncology medicine symbol on black as a 3D illustration.
3d computer illustration of a dendritic cell. They areantigen-presenting cells of the immune system. Their main function is to process antigen material and present it on the cell surface to the T cells of the immune system. They are messengers betwe
Immunologically active proteins on a T-cell. TCR (blue), CD-4 (light blue), CD-28 (dark blue), PD-1 (magenta), CTLA-4 (violet), Ca-channel (dark violet). The T-cell receptor, CD-4 and CD-28 activate T-cells, while PD-1 and CTLA-4 inhibit the activat
The T-cell receptor activates the immune response to antigens in T-lymphocytes. T-cell receptors (dark blue), CD4 molecules (light blue), glycolipids (orange). 3d rendering. Illustration
Human Cytotoxic T cell
Human Cytotoxic T cell
T Cells attacking Cancer Cells 3D illustration
T Cells attacking Cancer Cells 3D illustration
T Cells attacking Cancer Cells 3D illustration
T Cells attacking Cancer Cells 3D illustration
T Cells attacking Cancer Cells 3D illustration
T-cells attacking a cancer cell. Isolated on black background. 3d render
T Cells attacking Cancer Cells 3D illustration
T Cells attacking Cancer Cells 3D illustration
T Cells attacking Cancer Cells 3D illustration
T Cells attacking Cancer Cells 3D illustration
Human Cytotoxic T cell
T Cells attacking Cancer Cells 3D illustration
T Cells attacking Cancer Cells 3D illustration
T Cells attacking Cancer Cells 3D illustration
Dendritic cells present antigens (green) to lymphocytes through their membran bound MHC-molecules (violet). CD4 molecules (light blue) bind to other portions of the MHC, strengthening the interaction.
Human Cytotoxic T cell
Immune checkpoint inhibitors in cancer treatment, 3D illustration. Inhibitors of PD-1 receptor and PD-L1 prevent the tumour cell from binding to PD-1 and enable the T cell to remain active
The chemokine receptor 5 (CCR5) with a bound antagonist
T-cell receptor in complex with the MHC class II-peptide complex. The antigen (light green) is a peptide from a tumor cell, bacteria or virus. Different stages of the interaction. 3D-Rendering. Illustration
Human Antigene and bacteria
Immune checkpoint inhibitors in cancer treatment, 3D illustration. Inhibitors of PD-1 receptor and PD-L1 prevent the tumour cell from binding to PD-1 and enable the T cell to remain active
T-cell receptor in complex with the MHC class II-peptide complex. The antigen (light green) is a peptide from a tumor cell, bacteria or virus. Complex embedded in the membranes. 3D-Rendering. Illustration
Immunotherapy lymphocyte Cells
PD-1 (red) extends from the surface of a T-cell and interacts with the ligand protein PD-L1 (yellow) from a antigen presenting cell. Although the T-cell has been activated through the interaction of a T-cell receptor (blue) and a MHC protein (viole
Interaction of MHC-II (red) with the T-cell receptor (blue) and CD4 (light blue) and B7-1 (orange) with CD-28 (dark blue) activates T-cells while the interaction of P7-1 with CTLA-4 (violett) and PD-L1 (yellow) with PD-1 deactivates T-cells
Cancer cells express PD-L1 (orange) proteins on their surface to trick the immune system. The interaction of PD-L1 with PD-1 of T-cells leads to a down-regulation of T-cells. The antibody (yellow) blocks this interaction.
3d computer illustration of a chimeric antigen receptor. CARs are engineered cell receptors that allow T cells to recognize/attack specifically cancer cells. A signal protein is attached to the intracellular domain.
T-cell receptors are similar to one arm of an antibody. Like antibodies, they are composed of two chains. The binding site is at the tip of the molecule,
3d computer illustration of a chimeric antigen receptor. CARs are engineered cell receptors that allow T cells to recognize/attack specifically cancer cells. A signal protein is attached to the intracellular domain.
Engineered receptors (light blue) on the surface of a T-lymphocyte bind specifically to CD19-antigen molecules (magenta) on a leukemia cell. This activates a signal cascade in the T-cell leading to the apoptosis of the cancer cell.
CAR T cell therapy in Multiple myeloma (MM) - isometric view 3d illustration
Human Cell Receptor Antibodies in Immune Response

« Vorherige  1  2  3